• / Free eNewsletters & Magazine
  • / My Account

AES

SPDR® S&P Homebuilders ETF XHB 2 Star

Last Price$38.51Day Change (%)-0.28%
Open Price$38.56Day Change ($)-0.11
Day Range38.42–38.6652-Week Range30.92–39.22

As of Fri 6/22/2017 9:00:00 PM | USD

  1. All
  2. Morningstar Articles
  3. 3rd Party
  4. Investing
  1. UPDATE: This S&P 500 sector has actually gotten cheaper as the stock market trades near records

    UPDATE: This S&P 500 sector has actually gotten cheaper as the stock market trades near records

  2. UPDATE: This S&P 500 sector has actually gotten cheaper as the stock market trades near records

    UPDATE: This S&P 500 sector has actually gotten cheaper as the stock market trades near records

  3. UPDATE: This S&P 500 sector has actually gotten cheaper as the stock market trades near records

    UPDATE: This S&P 500 sector has actually gotten cheaper as the stock market trades near records

  4. UPDATE: This S&P 500 sector has actually gotten cheaper as the stock market trades near records

    UPDATE: This S&P 500 sector has actually gotten cheaper as the stock market trades near records

  5. UPDATE: This S&P 500 sector has actually gotten cheaper as the stock market trades near records

    UPDATE: This S&P 500 sector has actually gotten cheaper as the stock market trades near records

  6. UPDATE: This S&P 500 sector has actually gotten cheaper as the stock market trades near records

    UPDATE: This S&P 500 sector has actually gotten cheaper as the stock market trades near records

  7. Dayton Power and Light is Activating and Energizing Girls in Science

    Dayton Power and Light is Activating and Energizing Girls in Science

  8. Pfizer Announces Results from XELJANZ® (tofacitinib citrate) ORAL Strategy Study Published in The Lancet and Presented at the EULAR Annual Congress

    Pfizer Announces Results from XELJANZ® (tofacitinib citrate) ORAL Strategy Study Published in The Lancet and Presented at the EULAR Annual Congress

  9. Phase 2a Safety and Efficacy Data Support Further Development of Oral CC-220 in Patients with Lupus

    Phase 2a Safety and Efficacy Data Support Further Development of Oral CC-220 in Patients with Lupus

  10. Extended Follow-Up Data Evaluating Opdivo (nivolumab) Shows Durable Response in Adult Patients with Relapsed or Progressed Classical Hodgkin Lymphoma

    Extended Follow-Up Data Evaluating Opdivo (nivolumab) Shows Durable Response in Adult Patients with Relapsed or Progressed Classical Hodgkin Lymphoma

1234

©2017 Morningstar Advisor. All right reserved.